Atricure, Inc. (ATRC)
NASDAQ:ATRC
Want to see ATRC full AI Analyst Report?
ATRC Stock Chart & Stats
$29.37
$0.79(2.42%)
At close: 4:00 PM EST
$29.37
$0.79(2.42%)
Day’s Range― - ―
52-Week Range$27.26 - $43.18
Previous CloseN/A
Volume180.64K
Average Volume (3M)578.33K
Market Cap
$1.43B
Enterprise Value$1.38B
Total Cash (Recent Filing)$167.43M
Total Debt (Recent Filing)$88.02M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 05, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding49,809,902
10 Day Avg. Volume576,400
30 Day Avg. Volume578,328
Financial Highlights & Ratios
PEG Ratio2.21
Price to Book (P/B)3.84
Price to Sales (P/S)3.53
P/FCF Ratio39.12
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda117.87
Forecast
1Y Price Target
$49.29Price Target Upside67.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.05
Revenue Forecast (FY)$603.19M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ExpansionAnalyst believes ongoing clinical trials testing devices for stroke prevention and reduction of postoperative atrial fibrillation could broaden indications to include many more cardiac surgery patients, materially increasing the addressable market.
Product Resilience And Competitive MoatAnalyst highlights AtriClip's extensive clinical data, durable market position, and traction in pain management and open ablation as factors that should help defend share against larger competitors.
Profitability And MarginsManagement reported positive net income and improving gross and operating margins, supporting expectations for sustained profitability and stronger cash generation.
Bears Say
Minimally Invasive Surgery WeaknessAnalyst notes ongoing challenges in minimally invasive surgery revenue that could weigh on overall growth given the company's exposure across multiple product lines.
New Competitor Market RiskAnnouncement of a new surgical appendage closure device from a large competitor raises uncertainty and could pressure market share in key cardiac surgery segments.
Valuation And Investor SentimentAnalyst lowered the rating due to increased uncertainty from new competition, which may justify a lower valuation multiple and invite near-term investor selling pressure.
Atricure News
ATRC FAQ
What was Atricure, Inc.’s price range in the past 12 months?
Atricure, Inc. lowest stock price was $27.26 and its highest was $43.18 in the past 12 months.
What is Atricure, Inc.’s market cap?
Atricure, Inc.’s market cap is $1.43B.
When is Atricure, Inc.’s upcoming earnings report date?
Atricure, Inc.’s upcoming earnings report date is May 05, 2026 which is in 19 days.
How were Atricure, Inc.’s earnings last quarter?
Atricure, Inc. released its earnings results on Feb 17, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.087 by $0.127.
Is Atricure, Inc. overvalued?
According to Wall Street analysts Atricure, Inc.’s price is currently Undervalued.
Does Atricure, Inc. pay dividends?
Atricure, Inc. does not currently pay dividends.
What is Atricure, Inc.’s EPS estimate?
Atricure, Inc.’s EPS estimate is -0.06.
How many shares outstanding does Atricure, Inc. have?
Atricure, Inc. has 49,809,902 shares outstanding.
What happened to Atricure, Inc.’s price movement after its last earnings report?
Atricure, Inc. reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.087. Following the earnings report the stock price went down -2.153%.
Which hedge fund is a major shareholder of Atricure, Inc.?
Currently, no hedge funds are holding shares in ATRC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atricure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.29 (67.82% Upside)
$49.29 (67.82% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 72.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $149.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.23%
12-Months-Change
Fundamentals
Return on Equity
-2.43%
Trailing 12-Months
Asset Growth
7.36%
Trailing 12-Months
Company Description
Atricure, Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
ATRC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong revenue growth (FY2025 +14.9%), significant profitability improvement (adjusted EBITDA nearly doubled vs. prior year), solid cash generation, multiple product and clinical milestones (LeAAPS enrollment completed, BoxX‑NoAF launched, EnCompass adoption, new product launches), and reaffirmed 2026 guidance. Offsetting these positives are meaningful headwinds in the minimally invasive/hybrid Afib franchise driven by rapid PFA adoption, localized reimbursement challenges in the U.K., and new competitive entrants in the appendage market. Management expects the MIS pressure to moderate and has modeled modest competitive impacts into guidance while emphasizing operating leverage and continued investment in clinical evidence and innovation.View all ATRC earnings summariesATRC Stock 12 Month Forecast
Average Price Target
$49.29
▲(67.82% Upside)
Technical Analysis
Ownership Overview
4.02% Insiders
42.63% Mutual Funds
28.00% Other Institutional Investors
9.24% Public Companies and
Individual Investors